Ms. Roselyn Mae Lalonde, LPC-S, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 600 E. Taylor, Suite 4004, Sherman, TX 75090 Phone: 903-892-2874 Fax: 903-891-9064 |
Kaitlyn R Davis, LMFT Marriage & Family Therapist Medicare: Medicare Enrolled Practice Location: 315 W Mclain Dr, Sherman, TX 75092 Phone: 903-957-4701 |
Abigail Hill, LMFT-A Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 910 Cottonwood Dr, Sherman, TX 75090 Phone: 903-957-0440 |
Ms. Vicki Lynn Jukes, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 315 W Mclain Dr, Sherman, TX 75092 Phone: 903-357-2196 |
News Archive
Chronic exposure to cocaine reduces the expression of a protein known to regulate brain plasticity, according to new, in vivo research on the molecular basis of cocaine addiction. That reduction drives structural changes in the brain, which produce greater sensitivity to the rewarding effects of cocaine.
DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today presented updated clinical data from its Phase I/II study of lead product candidate VAL-083 (dianhydrogalactitol), in patients with refractory glioblastoma multiforme (GBM), at GBM2015: 2nd International Symposium on Clinical and Basic Investigation in Glioblastoma in Toledo, Spain.
If you think the air outside is polluted, a new research report in the September 2009 issue of the journal Genetics (http://www.genetics.org) might make you to think twice about the air inside our bodies too. That's because researchers show how about 3 percent of the air we breathe gets converted into harmful superoxides, which ultimately harm our muscles.
Advanced Cancer Therapeutics (ACT), a for-profit private company dedicated to bringing new anti-cancer therapies to market, today announced that it has secured $10 million in investments from high net-worth individuals and institutions. This round of investment, which closed six months ahead of the company's year-end goal, will provide ACT additional capital to continue its development and commercialization of potentially lifesaving therapeutics for cancer patients.
Optimer Pharmaceuticals, Inc. announced today the presentation of information from insurance claims and survey databases highlighting the unmet need for targeted therapies to treat subpopulations at high risk of recurrence of Clostridium difficile infection.
› Verified 9 days ago